# Scribe Therapeutics

engineered CasX (X-edit) CRISPR platform, partnered with Sanofi on in-vivo editing.


Source: https://bioecon.ru/companies/scribe-therapeutics/
Updated: 2026-07-29

- Страна: United States

## Проверяемые факты

| Факт | Значение | Источник |
| --- | --- | --- |
| Финансирование | IPO на $128.7 million (июль 2026 г.) и ~$150 million привлечено до IPO | https://endpoints.news/gene-editor-scribe-starts-second-half-ipo-spree-with-129m-listing/, https://medcitynews.com/2026/07/scribe-therapeutics-ipo-crispr-genetic-medicine-pcsk9-ascvd-sctx/, https://www.sec.gov/Archives/edgar/data/1853921/000119312526294804/d21355ds1.htm |
| Финансирование | Грантовое финансирование от CIRM до ~$25.7 млн | https://medcitynews.com/2026/07/scribe-therapeutics-ipo-crispr-genetic-medicine-pcsk9-ascvd-sctx/, https://www.biospace.com/scribe-therapeutics-announces-research-collaboration-with-sanofi-to-accelerate-breakthrough-crispr-based-cell-therapies-for-cancer, https://www.scribetx.com/newsroom/scribe-therapeutics-awarded-more-than-25-million-from-cirm-to-accelerate-additional-crispr-based-gene-editing-therapies-for-cardiometabolic-disease-into-clinical-trials, https://www.sec.gov/Archives/edgar/data/1853921/000119312526294804/d21355ds1.htm |
| Численность | от 88 до 89 сотрудников по состоянию на середину 2026 г. | https://stockanalysis.com/stocks/sctx/employees/ |
| Штаб-квартира | 1150 Marina Village Parkway, Аламида, Калифорния 94501, США | https://medcitynews.com/2026/07/scribe-therapeutics-ipo-crispr-genetic-medicine-pcsk9-ascvd-sctx/, https://www.sec.gov/Archives/edgar/data/1853921/000119312526294804/d21355ds1.htm, https://www.sec.gov/Archives/edgar/data/1853921/000119312526308330/d21355dex1013.htm |
| Регуляторное одобрение | разрешение австралийского регулятора TGA на клиническое исследование STX-1150 фазы 1 (май 2026 года) | https://medcitynews.com/2026/07/scribe-therapeutics-ipo-crispr-genetic-medicine-pcsk9-ascvd-sctx/, https://www.sec.gov/Archives/edgar/data/1853921/000119312526294804/d21355ds1.htm |
| Партнёрство | Стратегическое сотрудничество с Sanofi (in vivo и ex vivo) и Eli Lilly (неврология/нервно-мышечные заболевания) | https://www.biospace.com/scribe-therapeutics-announces-research-collaboration-with-sanofi-to-accelerate-breakthrough-crispr-based-cell-therapies-for-cancer, https://www.sec.gov/Archives/edgar/data/1853921/000119312526294804/d21355ds1.htm, https://www.sec.gov/Archives/edgar/data/1853921/000119312526308330/d21355dex1013.htm |
| Производственная площадка | Использует сторонние контрактные производственные организации (CMO) | https://www.sec.gov/Archives/edgar/data/1853921/000119312526294804/d21355ds1.htm, https://www.sec.gov/Archives/edgar/data/1853921/000119312526308330/d21355dex1013.htm |

Независимые источники: biospace.com, endpoints.news, medcitynews.com, scribetx.com, sec.gov, stockanalysis.com

## Технологии

- [Редактирование генома](https://bioecon.ru/technology/genome-editing/)